Search Results for: Immunogenicity

March 24, 2025March 24, 2025

Effective preparation and immunogenicity analysis of antigenic proteins for prevention of porcine enteropathogenic coronaviruses PEDV/TGEV/PDCoV.

Publication date: Mar 21, 2025 Porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis virus (TGEV) and porcine deltacoronavirus (PDCoV) cause highly contagious gastrointestinal damage to piglets with high coinfection in clinical. ... Read more

March 24, 2025March 24, 2025

Alcohol consumption does not influence SARS-CoV-2 vaccine immunogenicity: A stop the spread Ottawa cohort analysis.

Coronavirus Literature

Publication date: Mar 22, 2025 The effect of alcohol consumption on COVID-19 vaccine immunogenicity was evaluated. Participants from the Stop the Spread Ottawa cohort were categorized by alcohol consumption categorized ... Read more

March 22, 2025March 22, 2025

Molecular basis of Ad5-nCoV vaccine-induced immunogenicity.

Coronavirus Literature

Publication date: Mar 11, 2025 Ad5-nCoV (Convidecia) is listed for emergency use against COVID-19 by the World Health Organization (WHO) and has been globally administered to millions of people. It ... Read more

March 19, 2025March 19, 2025

Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting.

Tuberculosis Literature

Publication date: Mar 17, 2025 Safer and more effective tuberculosis (TB) vaccines than Bacille Calmette GucE9rin (BCG) are needed. We evaluated the safety, reactogenicity, and immunogenicity of three dose levels ... Read more

$Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in Brazil.$

March 15, 2025March 15, 2025

Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in Brazil.

Coronavirus Literature

Publication date: Apr 01, 2025 Fractional doses of vaccine to protect against COVID-19 offer the potential to expand vaccine availability, reduce side effects, and enhance vaccination campaign efficiency. This study ... Read more

March 15, 2025March 15, 2025

Bioinformatics analysis, immunogenicity, and therapeutic efficacy evaluation of a novel multi-stage, multi-epitope DNA vaccine for tuberculosis.

Tuberculosis Literature

Publication date: Mar 13, 2025 The global tuberculosis (TB) epidemic remains severe. We aimed to develop a therapeutic DNA vaccine as an adjunct to TB treatment to improve efficacy. The ... Read more

March 14, 2025March 14, 2025

Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial.

Tuberculosis Literature

Publication date: Mar 05, 2025 People with tuberculosis who complete treatment remain at risk of recurrent disease. The vaccine H56:IC31 has been shown to be safe and immunogenic in phase ... Read more

March 11, 2025March 11, 2025

Post hoc analysis: 6 Months immunogenicity after third dose of BNT162b2 vs JNJ-78,436,735 after two doses of BNT162b2 vaccine in solid organ transplant recipients.

Coronavirus Literature

Publication date: Jun 01, 2025 In Solid Organ Transplant (SOT) recipients, due to immunosuppression, the immunogenicity after COVID-19 vaccination is suboptimal and its durability is unknown. We conducted a post-hoc ... Read more

March 11, 2025March 11, 2025

Link of TMPRSS2 expression with tumor immunogenicity and response to immune checkpoint inhibitors in cancers.

Coronavirus Literature

Publication date: Mar 07, 2025 SARS-CoV-2 and other viruses rely on the protease function of the TMPRSS2 protein to invade host cells. Despite cancer patients often experience poorer outcomes following ... Read more

March 11, 2025March 11, 2025

Link of TMPRSS2 expression with tumor immunogenicity and response to immune checkpoint inhibitors in cancers.

Coronavirus Literature